Open Access<p>The Multifunction Of miR-218-5p-Cx43 Axis In Breast Cancer</p>
Author(s) -
Xia Chen,
Hong Jiang,
Fugui Ye,
Zhuang Zhang
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s218524
Subject(s) - gemcitabine , microrna , cancer research , epigenetics , breast cancer , western blot , cell growth , transfection , cell culture , chemistry , microbiology and biotechnology , biology , cancer , medicine , gene , biochemistry , genetics
Gemcitabine is proven to be the first-line standard treatment of breast cancers. Yet, little is known involving gemcitabine resistance and remains largely to be elucidated.